

Brittany L Murphy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7295336/publications.pdf>

Version: 2024-02-01

32
papers

525
citations

759055

12
h-index

677027

22
g-index

32
all docs

32
docs citations

32
times ranked

925
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes. <i>Annals of Surgical Oncology</i> , 2018, 25, 2241-2248.	0.7	99
2	Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties. <i>Annals of Surgical Oncology</i> , 2019, 26, 3920-3930.	0.7	65
3	A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. <i>Annals of Surgical Oncology</i> , 2017, 24, 2915-2924.	0.7	47
4	Validation of the AAST EGS acute cholecystitis grade and comparison with the Tokyo guidelines. <i>Surgery</i> , 2018, 163, 739-746.	1.0	44
5	Trends of inguinal hernia repairs performed for recurrence in the United States. <i>Surgery</i> , 2018, 163, 343-350.	1.0	24
6	Factors Associated With Positive Margins in Women Undergoing Breast Conservation Surgery. <i>Mayo Clinic Proceedings</i> , 2018, 93, 429-435.	1.4	21
7	Breast cancer-related paraneoplastic neurologic disease. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 771-778.	1.1	20
8	Breast Cancer Litigation in the 21st Century. <i>Annals of Surgical Oncology</i> , 2018, 25, 2939-2947.	0.7	20
9	Nipple-sparing Mastectomy for the Management of Recurrent Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, e209-e213.	1.1	19
10	Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes. <i>Clinical Breast Cancer</i> , 2018, 18, e501-e506.	1.1	19
11	Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2518-2525.	0.7	17
12	Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3510-3517.	0.7	17
13	Pain and opioid prescriptions vary by procedure after breast surgery. <i>Journal of Surgical Oncology</i> , 2019, 120, 593-602.	0.8	14
14	Cross-sectional imaging to evaluate the extent of regional nodal disease in breast cancer patients undergoing neoadjuvant systemic therapy. <i>European Journal of Radiology</i> , 2017, 89, 163-168.	1.2	12
15	Management of the axilla in metaplastic breast carcinoma. <i>Gland Surgery</i> , 2018, 7, 200-206.	0.5	11
16	99mTc-Tilmanocept Versus 99mTc-Sulfur Colloid in Lymphoscintigraphy: Sentinel Lymph Node Identification and Patient-Reported Pain. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 300-304.	0.4	10
17	Outcomes and feasibility of nipple-sparing mastectomy for node-positive breast cancer Patients. <i>American Journal of Surgery</i> , 2017, 213, 810-813.	0.9	9
18	Contemporary operative management of T4 breast cancer. <i>Surgery</i> , 2016, 160, 1059-1069.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Contralateral Prophylactic Mastectomy for Women with T4 Locally Advanced Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3365-3370.	0.7	7
20	Validation of the American Association for the Surgery of Trauma's emergency general surgery breast infection grading system. <i>Journal of Surgical Research</i> , 2018, 228, 263-270.	0.8	7
21	Selective Use of Sentinel Lymph Node Surgery in Patients Undergoing Prophylactic Mastectomy Using Intraoperative Pathology. <i>Annals of Surgical Oncology</i> , 2017, 24, 3032-3037.	0.7	6
22	Patient-reported experience after outpatient breast surgery. <i>American Journal of Surgery</i> , 2019, 218, 175-180.	0.9	5
23	Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients: When to Stop?. <i>Annals of Surgical Oncology</i> , 2021, 28, 888-893.	0.7	5
24	Minimal cosmetic revision required after minimally invasive pectus repair. <i>Pediatric Surgery International</i> , 2018, 34, 775-780.	0.6	4
25	Returns to the operating room after breast surgery at a tertiary care medical center. <i>American Journal of Surgery</i> , 2019, 218, 388-392.	0.9	4
26	A Picture is Worth a Thousand Words: Intraoperative Photography as a Quality Metric for Axillary Dissection. <i>Annals of Surgical Oncology</i> , 2016, 23, 3494-3500.	0.7	3
27	Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy. <i>Journal of Surgical Oncology</i> , 2017, 116, 213-219.	0.8	3
28	ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time—Highest Rates of Use Now in Triple-Negative and HER2+ Disease. <i>Annals of Surgical Oncology</i> , 2018, 25, 695-696.	0.7	3
29	Surgical Treatment of Adolescent Breast Disorders: Institutional Experience and National Trends. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2018, 31, 299-303.	0.3	1
30	A rare case of a 65-year old female with a mesenteric paraganglioma. <i>Human Pathology: Case Reports</i> , 2020, 19, 200349.	0.2	1
31	Response to HER2 status might be independent determinant associated with no residual disease at surgical resection in patients with DCIS. <i>Journal of Surgical Oncology</i> , 2017, 116, 791-791.	0.8	0
32	ASO Author Reflections: Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients Can Stop After Removal of Three Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2020, 27, 848-849.	0.7	0